

-continued

ggggccctca ccagcgagggt gcacacttc cccgcccgtgc tgcaatcctc cggcctgtac	600
agectgtctt ccgtcggtac tggcgcttagc tcctccctgg gaaccaggac ctacatctgc	660
aacgtgaacc acaaggccctc caacaccaag gtcgacaaga aggtcgaacc gaagtctgtgc	720
gacaagactc atacgtgccc tccttgccc gccccggaaac tgctgggagg cccatccgt	780
tccctgttcc caccaagcc taaggatacc ctgtatgtatc gcagaacacc ggaagtgacc	840
tgtgtggtagg tggacgtcag ccacgaagat cccgaggtaa agttcaattt gtacgtggac	900
gggggtggagg tgcacaacgc aaagaccaag ccccgaggagg aacagtacaa ctccacctat	960
cgcgtggtgtt cgggtgtgac ggtgtgtcac caggactggt tgaacggaaa ggagtataag	1020
tgcaaaagtgtt cgaacaaggc cctggccgtc cctatcgaaa agaccatctc caaggccaag	1080
ggccagccgc gggaaacccca ggtctacact ctccaccga gccgcgacga actgactaag	1140
aatcaagtgtt cgctgtaccc cctctgtcaag ggcttctacc cgtccgacat cggcgtggaa	1200
tgggagagca acggccagcc ggaaaacaac tacaagacca cccctccgt gctggattcc	1260
gacgggtctt ttttctgtta ctcaaactg accgtggata agtccagatg gcagcaggc	1320
aatgtctttt catgtccgt gatgcacgag gctctgcata accactacac ccagaagtgc	1380
ctgtccctgtt ccccgggaa gtga	1404

<210> SEQ ID NO 30

<211> LENGTH: 22

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 30

Met	Val	Ser	Glu	Phe	Leu	Lys	Gln	Ala	Trp	Phe	Ile	Glu	Asn	Glu	Glu
1				5				10				15			

Gln	Glu	Tyr	Val	Gln	Thr
	20				

<210> SEQ ID NO 31

<211> LENGTH: 25

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Ala	Met	Val	Ser	Glu	Phe	Leu	Lys	Gln	Ala	Trp	Phe	Ile	Glu	Asn	Glu
1					5			10				15			

Glu	Gln	Glu	Tyr	Val	Gln	Thr	Val	Lys
	20						25	

1. A specific binding molecule which binds human Anx-A1 for use in the treatment of cancer in a subject, wherein:

(i) said specific binding molecule comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each of said CDRs having an amino acid sequence as follows:

VLCDR1 has the sequence set forth in SEQ ID NO: 1, 7 or 8;

VLCDR2 has the sequence set forth in SEQ ID NO: 2;

VLCDR3 has the sequence set forth in SEQ ID NO: 3;

VHCDR1 has the sequence set forth in SEQ ID NO: 4;

VHCDR2 has the sequence set forth in SEQ ID NO: 5; and

VHCDR3 has the sequence set forth in SEQ ID NO: 6; or, for each sequence, an amino acid sequence with at least 85% sequence identity thereto; and/or

(ii) said specific binding molecule binds to Anx-A1 at a discontinuous epitope consisting of amino acids 197-206, 220-224 and 227-237 of SEQ ID NO: 17.

2. The specific binding molecule for use according to claim 1, wherein:

VLCDR1 has the sequence set forth in SEQ ID NO: 1; VLCDR2 has the sequence set forth in SEQ ID NO: 2; VLCDR3 has the sequence set forth in SEQ ID NO: 3; VHCDR1 has the sequence set forth in SEQ ID NO: 4;